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Targeted Capture and Next-Generation Sequencing
Identifies C9orf75, Encoding Taperin, as the Mutated
Gene in Nonsyndromic Deafness DFNB79
Atteeq Ur Rehman,1,2 Robert J. Morell,1 Inna A. Belyantseva,1 Shahid Y. Khan,2 Erich T. Boger,1
Mohsin Shahzad,2 Zubair M. Ahmed,3,4 Saima Riazuddin,5 Shaheen N. Khan,2 Sheikh Riazuddin,6
and Thomas B. Friedman1,*
Targeted genome capture combined with next-generation sequencing was used to analyze 2.9 Mb of the DFNB79 interval on chromo-
some 9q34.3, which includes 108 candidate genes. Genomic DNA from an affected member of a consanguineous family segregating
recessive, nonsyndromic hearing loss was used to make a library of fragments covering the DFNB79 linkage interval deﬁned by genetic
analyses of four pedigrees. Homozygosity for eight previously unreported variants in transcribed sequences was detected by evaluating
a library of 402,554 sequencing reads and was later conﬁrmed by Sanger sequencing. Of these variants, six were determined to be poly-
morphisms in the Pakistani population, and one was in a noncoding gene that was subsequently excluded genetically from the DFNB79
linkage interval. The remaining variant was a nonsense mutation in a predicted gene, C9orf75, renamed TPRN. Evaluation of the other
threeDFNB79-linked families identiﬁed three additional frameshift mutations, for a total of four truncating alleles of this gene. Although
TPRN is expressed inmany tissues, immunolocalization of the protein product in the mouse cochlea shows prominent expression in the
taper region of hair cell stereocilia. Consequently, we named the protein taperin.Introduction
The initial identiﬁcation of pathogenic mutations at a
genetic locus can be challenging when the linkage interval
includes a large number of genes. The conventional
strategy has been to sequence the coding regions of each
gene in a critical interval one by one, after rank ordering
them on the basis of hypotheses about gene function or
expression pattern. We previously applied this approach
to the nonsyndromic recessive deafness locus DFNB79,
which we mapped to a 3.84 Mb linkage interval on chro-
mosome 9q34.3.1 This interval contains 113 predicted
and reported genes. We excluded eight candidate genes,
including NOTCH1 (MIM 190198) and CACNA1B (MIM
601012), by using dideoxy-terminator sequencing.1
Continuing this hierarchical approach of sequencing
exons of candidate genes seemed impractical because of
the large number of genes at the DFNB79 locus. Moreover,
our experience with other nonsyndromic deafness genes is
that they often are the ones that initially seem unlikely
because of a nearly ubiquitous pattern of expression,
such as ACTG1 (MIM 102560),2,3 TRIC (MIM 610572),4
TMPRSS3 (MIM 605511),5 LRTOMT (MIM 612414),6 and
HGF (MIM 142409),7 and pathogenic alleles are sometimes
found in a noncoding region, such as those that were
found to occur in HGF.7
Recent advances in technology have made it possible to
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We applied targeted genome capture by using aNimbleGen
array and high-throughput Roche 454 sequencing to the
genomic DNA of an affected individual from a DFNB79-
linked family. We identiﬁed a nonsense mutation in a pre-
dicted gene, C9orf75, designated TPRN, and subsequently
identiﬁed three additional frameshift mutations in the
same gene in the other three DFNB79-linked families.
RT-PCR analysis revealed that transcripts from this gene
are expressed in many tissues, including the cochlea. Our
immunolocalization results demonstrate that, in themouse
cochlea, the protein encoded by Tprn is localized promi-
nently at the taper regions of hair cell stereocilia. This is
the region near the base of stereocilia where the diameter
of stereocilia gradually narrows before insertion into the
cuticular plate. On the basis of the immunolocalization in
inner ear hair cells, we have named the protein taperin.Subjects and Methods
Family Enrollment and Diagnosis
Ascertainment and enrollmentmethodology for family PKDF1129
was the same as that which has been described for families
PKDF741, PKDF517, and PKDF280.1 Written informed consent
was obtained for all study participants after approval from the
Combined Neuroscience Institutional Review Board (IRB) at
the National Institutes of Health (NIH), Bethesda, MD, USA, and
the IRB at the National Centre of Excellence in Molecular Biologyr Communication Disorders, National Institutes of Health, Rockville, MD
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Figure 1. DFNB79-Linked Pedigrees and Sequence Traces Showing Pathogenic Variants
(A) Affected individual IV-4 from family PKDF741 was selected for NimbleGen capture and enrichment of genomic DNA from the
DFNB79 locus and next-generation sequencing. Filled symbols in each pedigree represent affected individuals. A dot in the upper right
corner of symbols for females (circles) and males (squares) indicates an individual whose DNA sequence of TPRN was determined via
dideoxy-terminator chemistry. Bars below the DNA sequence indicate altered nucleotide(s). In family PKDF280, the sequence trace
from an affected individual shows a homozygous 11 bp duplication. In an affected individual from family PKDF1129, dotted lines indi-
cate the location of the 11 bp deletion. NCBI Reference Sequences (NM_001128228.1 for nucleotide change and NP_001121700 for
amino acid change) were used to indicate positions of mutations in cDNA and protein, respectively.
(B) The 11 bp deletion and 11 bp duplication found in affected members of families PKDF1129 and PKDF280, respectively, occur in
sequence that is already duplicated in the wild-type.(NCEMB), University of the Punjab, Lahore, Pakistan. Hearing in
affected individuals was evaluated by pure-tone audiometry. Fun-
duscopic, tandem gait, and Romberg tests were performed to assess
vision loss and vestibular dysfunction. Affected individuals from
DFNB79-linked pedigrees exhibited prelingual, bilateral, severe
to profound sensorineural hearing loss, and apparently normal
vestibular function on the basis of Romberg and tandem gait
testing. There were no other obvious clinical ﬁndings.1 Blood
samples were obtained from study participants and DNA was
extracted as previously described.12
NimbleGen Target-Region Capture
A custom Sequence Capture 385K Human Array was designed and
manufactured by Roche NimbleGen. A total of 385,000 unique,The Amerioverlapping probes 60–90 nucleotides in length were designed
across the DFNB79 target region (chromosome 9: 137,372,128–
140,273, 252; NCBI build 36.1, hg18). Probe uniqueness was
determined by the Sequence Search and Alignment by Hashing
Algorithm (SSAHA).13 Probe tiling of the target region excludes
repetitive DNA, and adjacent coding regions are sometimes sacri-
ﬁced. Approximately 20 mg of genomic DNA from affected indi-
vidual IV-4 of family PKDF741 (Figure 1A) was fragmented to
a size range of 300–500 base pairs (bp) with the use of a GS Nebu-
lizer Kit (Roche Applied Science). The fragmented DNA
was puriﬁed (DNA Clean & Concentrator-25, Zymo Research)
and analyzed on an Agilent Bioanalyzer 2100 DNA Chip 7500
according to the manufacturer’s instructions. Fragment ends
were polished with the use of T4 DNA Polymerase and T4can Journal of Human Genetics 86, 378–388, March 12, 2010 379
Polynucleotide Kinase, and adapters were ligated onto the pol-
ished ends with T4 DNA Ligase. Small fragments (< 100 bp)
were removed with the use of AMPure Beads (Agencourt). The re-
sulting library was hybridized to a custom 385K array with the use
of the NimbleGen Sequence Capture Hybridization System 4. The
hybridized DNA from the DFNB79 target region was washed and
eluted with the use of a NimbleGen Wash and Elution Kit accord-
ing to themanufacturer’s instructions. There is a tradeoff in adjust-
ing the stringency of hybridization and wash conditions in order
to retain sufﬁcient on-target sequence while reducing the capture
of off-target sequence.14 The eluted sample was ampliﬁed by liga-
tion-mediated PCR with the use of primers complementary to the
sequence of the adaptors.454 Sequencing
Sequencing was performed on a Roche 454 FLX Titanium instru-
ment at SeqWright. Three micrograms of the eluted library, now
enriched for fragments from the DFNB79 interval, were size
selected (> 400 bp)withAMpure beads (Agencourt). Library immo-
bilization and single-strand isolationwas performedwith the use of
a GS FLX Titanium General Library Preparation Kit (Roche). The
library was puriﬁed with the use of MinElute PCR Puriﬁcation Kit
(QIAGEN) and then ampliﬁed on the sequencing beads by emul-
sion PCR. After bead recovery, bead enrichment, and sequencing-
primer annealing, the beadswere deposited on a 454 Picotiter Plate
and sequenced with the use of a GS FLX Titanium Kit XLR70
(Roche). The reads were assembled with Newbler Assembler (454
Life Sciences) and thenmapped to the humanhg18 assembly refer-
ence sequence (NCBI build 36.1). Fold enrichment of the target
region was calculated as described previously,15 with use of the
formula
P
REMTrm/STrm:
P
RMG/SG, in which REMTrm is the number
of reads mapped to the repeat masked target region, STrm is the size
of the repeatmasked target region, RMG is thenumber of readsmap-
ped to thehumangenome, andSG is the size of thehumangenome.
Putative variants were detected by GS Amplicon Variant Analyzer
software (454 Life Sciences) with a ﬁltering parameter such that
a variant should be supported by at least three nonduplicate
forward and reverse 454 reads, or at least ﬁve unidirectional reads,
with quality scores> 20 (or> 30 if the difference involved a homo-
polymer of ﬁve or more nucleotides or larger).Dideoxy-Terminator Sequencing
Primers (Integrated DNA Technologies) were designed with
Primer3 software. GC-rich genomic templates were ampliﬁed
with the use of Advantage GCGenomic LA Polymerase Mix (Clon-
tech) and the FailSafe PCR System (Epicenter Biotechnologies). All
previously unreported variants discovered in the transcribed
sequences of the DFNB79 target region and all exons of SNHG7
and TPRN were sequenced with the use of conventional di-
deoxy-terminator as described previously.16 Sequencing products
were resolved on an ABI3730 capillary sequencing instrument
(Applied Biosystems), and sequence traces were analyzed with La-
sergene 8 software (DNASTAR).Genotyping
Linkage to DFNB79 was established for family PKDF1129 during
the screening for linkage to all currently known nonsyndromic
deafness loci (DFNB), including DFNB79,1 with the use of STR
markers as previously described.17 Amplicons were resolved on
ABI Prism 3100 or ABI3730 instruments. Genotypes were analyzed
using GeneMapper software (Applied Biosystems).380 The American Journal of Human Genetics 86, 378–388, March 1RT-PCR Analysis of Tprn Expression
C430004E15Rik (RefSeq NM_175286.4), the mouse ortholog of
human TPRN, was ampliﬁed from two mouse multitissue cDNA
panels (Clontech MTC Panels I and III) and from mouse cochlear
cDNA that was prepared with a SMART kit and oligo-dT primers
(Clontech). The PCR primers (forward, 50-GTTCATGCGACTTG
AGTCGGAGCGG-30; reverse, 50-GGGCAGGAGCTTGGATTTCGG
CAAA-30) are located in exon 1 and in the 30 untranslated region
(UTR), respectively.
Expression Plasmids
Mouse full-length Tprn cDNA was PCR ampliﬁed from postnatal
day 5 inner ear cDNAwith LATaqDNA polymerase (TakaraMirus),
cloned into XL-TOPO vector (Invitrogen), and transformed into
DH5a bacteria (Invitrogen). A 2250 bp cDNA product encoding
the Tprn open reading frame was ampliﬁed with Pfu Ultra DNA
polymerase (Stratagene) and ligated into the EcoRI and SalI sites
of pAcGFP1-C2. A 1785 bp cDNA product encoding the open
reading frame of mouse phostensin was also ampliﬁed with Pfu
Ultra DNA polymerase from a full-length mouse cDNA clone
(Open Biosystems). The PCR product was ligated into the EcoRI
and SalI sites of the AcGFP1-C2 plasmid, and this plasmid was
transformed into XL10-Gold cells (Stratagene). For expression
plasmids, both strands of the cDNA inserts were veriﬁed with
Sanger sequencing.
Antibody Validation
To validate anti-taperin antibody (HPA020899; C9orf75, Sigma),
we performed a colocalization assay by using green ﬂuorescent
protein (GFP)-taperin- and GFP-phostensin-transfected COS7cells.
The cells were grown on coverslips in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen) until ~80% conﬂuency was achieved, then the cells
were transfected with Lipofectamine 2000 (Invitrogen). After incu-
bation at 37C with 5% CO2 for 24–36 hr, transfected COS7 cells
were ﬁxed with 4% paraformaldehyde (EMS) in PBS for 20 min
and permeabilized for 15 min in 0.2% Triton X-100 in 13 PBS.
Nonspeciﬁc binding sites were blocked by incubation in 2% BSA
and 5% normal goat serum in PBS for 30 min. Primary taperin
antibody was diluted in blocking solution to a ﬁnal concentration
of ~5 mg per ml. COS7 cells were incubated with taperin antibody
for 2 hr at room temperature, followed by incubation with Alexa
Fluor 568 goat anti-rabbit immunoglobulin G (Molecular Probes)
for 20 min at room temperature. Samples were washed in PBS,
mounted with ProLong Gold Reagent (Molecular Probes), and
imaged with the use of a LSM710 confocal microscope equipped
with a Zeiss 100X objective that has a numerical aperature of 1.4.
Fluorescence Immunostaining and Confocal
Microscopy
Whole-mounted organ of Corti and vestibular epithelium samples
were immunostained as described previously,18 with somemodiﬁ-
cations. In brief, cochleae were ﬁxed in 4% paraformaldehyde for
1.5 hr at room temperature and permeabilized in 0.5% Triton
X-100 for 30 min. Nonspeciﬁc binding sites were blocked in
13 PBS-based solution containing 2% BSA and 5% normal goat
serum for 1 hr at room temperature. Antiserum against a fragment
of human taperin 70 amino acids in length was obtained from
Sigma-Aldrich (HPA020899; C9orf75). The specimens were incu-
bated overnight at 4C with this primary antibody diluted in
blocking solution. This was followed by several washes in 13 PBS2, 2010
Table 1. NimbleGen Probe and 454 Sequencing Coverage Summary of 2.9 Mb Targeted DFNB79 Interval
Category Total Protein Coding
UTRs, Introns, and
Noncoding Genes Intergenic Region
Number of bases 2,871,073a 150,439 1,731,069 989,565
Probe coverage in bases 2,132,062 (74.26%) 141,019 (93.74%) 1,297,527 (74.95%) 693,516 (70.08%)
Sequence coverage in bases 2,220,820 (77.35%) 142,108 (94.46%) 1,338,676 (77.33%) 740,036 (74.78%)
Gaps in probe coverage 2498 99 1,508 958
Gaps in sequencing coverage 1264 50 812 493
Probe gap length range (mean) 1–25,940 (295.84) 1–1058 (95.15) 1–19,898 (287.49) 1–9,989 (309.03)
Sequencing gap range (mean) 2–49,014 (514.44) 8–886 (166.62) 1–35,906 (483.24) 4–9,989 (506.14)
See Table S1 as well.
a A gap of 31,051 bp in the DFNB79 interval is present in the NCBI 36 reference human genome sequence (hg18).and 20 min of incubation at room temperature in AlexaFluor ﬂuo-
rescein isothiocyanate (FITC)-conjugated secondary antibody
(Molecular Probes) at a 1:500 dilution and in rhodamine-phalloi-
din at 1:100 dilution in blocking solution. The specimens were
then processed as described above.Results
SNP Genotyping Reﬁnes the DFNB79 Interval
We reﬁned the DFNB79 linkage region1 from 3.84 Mb to
2.9 Mb through analysis of additional SNP genotypes.
This reduced the number of candidate genes from 113 to
108 (Table S1, available online). These 108 genes have
870 protein-coding exons comprising a total of 150 kb.
The UTRs, introns, and noncoding genes in this interval
span an additional 1731 kb, and intergenic regions encom-
pass 989 kb of genomic DNA (Table 1).Table 2. Summary Statistics of 454 Reads
Category Reads Base Calls
Total reads generated
by 454 sequencing
443,047 123,249,163
Read length range
(mean)
14–761 (278) -
Reads used for
assembly after
quality trimming
405,799 (91.59%)a 113,353,237 (91.97%)
Reads mapped to
human genome
402,554 (99.20%)b 111,498,382 (98.36%)
Reads not mapped
to human genome
3,245 (0.80%)b -
Mapped to multiple
places in human
genome
142,881 (35.50%)c -
Mapped to DFNB79
target region
156,019 (38.75%)c 42,752,954 (38.34%)
Off-target 103,654 (25.75%)c -
See Table S2 as well.
a Percentage of 443,047 reads generated by 454 sequencing.
b Percentage of quality filtered reads.
c Percentage of quality filtered reads mapped to the human genome.Targeted Genome Capture and Next-Generation
Sequencing
Using a custom NimbleGen array with probes covering
93.74% of the protein-coding sequence, 74.95% of UTRs,
introns, and noncoding genes, and 70.08% of intergenic
regions (Table 1), we enriched DNA for the reﬁned
DFNB79 locus and sequenced the captured library. A total
of 443,047 reads with an average length of 278 nucleotides
were produced, of which 405,799 (91.59%) were assem-
bled after adaptor and quality trimming (Table 2). We
found that 99.20% of the assembled reads mapped to the
human genome, of which 35.50% mapped to multiple
off-target locations and were not included in our down-
stream analyses. Of the assembled reads, 38.75% uniquely
mapped to the DFNB79 target region, whereas 25.75%
uniquely mapped across the human genome outside the
target region (Table 2 and Table S2). This represents a
561-fold enrichment of the repeat-masked target region.
Incidentally, the off-target reads included 94% coverage
of the mitochondrial genome, which allowed us to inspect
for reported mitochondrial mutations associated with
hearing loss,19 but we found none.The AmeriSequence coverage was, on average, 20-fold for 77.35%
of the DFNB79 target region. This included 94.46% of
the protein-coding region, 77.33% of the region covered
by introns, UTRs, and noncoding genes, and 74.78% of
the intergenic regions (Table 1). Of the remaining DFNB79
target region with limited coverage, one third was from
a subtelomeric region, which is difﬁcult to sequence.20
Moreover, there were protein-coding regions that were
represented by probes on the NimbleGen array but for
which no sequence was obtained. All of these regions
have high (average ¼ 75%) GC content (Table S3). Of the
108 genes in the DFNB79 interval, 52 were completely
sequenced and 53 were partially sequenced. Only three
genes were less than 10% sequenced: one was located
very close to the telomere and consequently could not
be represented on the NimbleGen array, and two werecan Journal of Human Genetics 86, 378–388, March 12, 2010 381
Figure 2. Summary of Variants Found by Next-Generation
Sequencing
Values in regular font are variants supported by at least three non-
duplicate forward and reverse 454 reads or at least ﬁve unidirec-
tional reads with a quality score greater then 20 (or 30 if the differ-
ence involved a pentamer or larger). Values in bold are restricted to
those variants supported by at least 85% of the reads mapped at
that location. Abbreviations are as follows: UTR, untranslated
region; STR, short tandem repeat; SNP, single-nucleotide polymor-
phism.
a False positives demonstrated by Sanger sequencing.small single-exon genes adjacent to repetitive sequences
(Table S1).
After ﬁltering for quality, there appeared to be a total of
2231 variants in the DFNB79 interval. Of these, 1928 were
reported in dbSNP, leaving 303 previously unreported vari-
ants (Figure 2). Seventeen of these were located in tran-
scribed regions of annotated or predicted genes. We chose
these variants for further analysis. Given the consan-
guinity in pedigree PKDF741 and our extensive genotyp-
ing data, we expected that affected individual IV-4 would
be homozygous for all variants at the DFNB79 locus. In
fact, the reads in contigs spanning the variants were not
always congruent. Nine of the 17 variants appeared to be
heterozygous because less than 85% of the contig reads
showed a difference from the hg18 reference sequence.
This apparent heterozygosity was most likely due to
poor-quality sequencing. We designed PCR primers to382 The American Journal of Human Genetics 86, 378–388, March 1amplify these 17 variants from the genomic DNA of indi-
vidual IV-4, and we sequenced the PCR products via
conventional Sanger sequencing. Only eight variants
were conﬁrmed as real, and all eight were homozygous
in individual IV-4. At the other nine sites of putative
sequence variation, individual IV-4 was homozygous for
the reference sequence. We assume that these nine false-
positive variants were 454-derived sequencing artifacts.
All of the eight conﬁrmed sequence variants cosegregate
with DFNB79 in family PKDF741, as determined by Sanger
sequencing of PCR products. We also evaluated these eight
variants in PCR products from at least 176 healthy Pakis-
tani control chromosomes, and we found that six are poly-
morphisms with allele frequencies ranging from 1.72% to
69.4% (Table 3).
Two of the variants, c.729C>T (NR_024542.1) and
c.1056G>A (NM_001128228.1), were not found in the Pak-
istani control chromosomes. c.729C>T (NR_024542.1) is
located in exon 4 of SNHG7, Small Nucleolar RNA Host
Gene 7, a four-exon, non-protein-coding gene. DNA
sequence of the four SNHG7 exons and approximately
50 bpof intronic regionﬂanking each exonwas determined
by Sanger sequencing of PCR products ampliﬁed from
genomic DNA of one affected individual from two other
DFNB79-linked pedigrees, PKDF280 and PKDF517. We did
not ﬁnd any variant in PKDF517. However, in PKDF280,
we found a 20 bp duplication, c.190_209dup (NR_
024542.1), in the ﬁrst exon of SNHG7. We determined
that c.190_209dup (NR_024542.1) is a polymorphism in
the Pakistani control group (Table 3), and it does not
cosegregate with deafness in family PKDF280. Two of the
18 affected individuals (V-4 and VI-16, Figure 1A) of
family PKDF280 are heterozygous for c.190_209dup (NR_
024542.1). These data provide evidence of a meiotic break-
point, which further reﬁnes the DFNB79 linkage interval
and excludes SNHG7 as a candidate gene. Prior to ascertain-
ment of family PKDF1129, SNHG7was excluded as a candi-
date DFNB79 gene and therefore was not sequenced in
family PKDF1129.
Identifying the DFNB79 Causative Gene
The remaining variant is c.1056G>A (NM_001128228.1),
located in a GC-rich ﬁrst exon (74% GC content) of
TPRN (C9orf75). The predicted open reading frame of
TPRN spans four exons and encodes 711 amino acids
(ENST00000409012). Exon 1 spans 1725 nucleotides and
encodes 81% (575 of the 711 residues) of the predicted
protein. The c.1056G>A (p.W352X) mutation is predicted
to introduce a premature stop codon and results in
a truncated protein of 412 amino acids, renders the tran-
script susceptible to nonsense-mediated RNA decay,21 or
both. PCR products encompassing all coding exons,
including approximately 50 bp of ﬂanking intronic
sequence, of TPRN were ampliﬁed from genomic DNA of
individuals in the other three DFNB79-linked pedigrees
(PKDF517, PKDF280, and PKDF1129) and were sequenced
via dideoxy-terminator chemistry. We found a 1 bp2, 2010
Table 3. Variants Found in Transcribed Regions of DFNB79 Interval and their Allele Frequencies
Family Gene Mutation Location
Pakistani Control
Chromosomes
Coriell HD200CAU
Panel Comment
PKDF280 TPRN c.44_54dup (NM_001128228.1) 0/488 0/400 Pathogenic variant
PKDF517 TPRN c.1244 delC (NM_001128228.1) 0/500 0/400 Pathogenic variant
PKDF741 TPRN c.1056G>A (NM_001128228.1) 0/500 0/400 Pathogenic variant
PKDF1129 TPRN c.42_52 del (NM_001128228.1) 0/488 0/400 Pathogenic variant
PKDF741 QSOX2a c.*587_*588delGT (NM_181701.3) 4/174 - SNPc
PKDF741 C9orf167 c.-73G>A (NM_017723.2) 4/174 - SNPc
PKDF741 C9orf167 c.*1641G>A (NM_017723.2) 3/174 - SNPc
PKDF741 LOC100133077 c.*483C>T (AK128414.1) 2/174 - SNPc
PKDF741 GPSM1a c.1959C>T (NM_001145638.1) 6/160 - SNPc
PKDF741 GPSM1a c.*207GGGCT[56] (NM_015597.4) 111/160 - STR
PKDF741 SNHG7b c.729C>T (NR_024542.1) 0/176 - Rare variant
PKDF280 SNHG7b c.190_209dup (NR_024542.1) 13/172 - SNPd
The following abbreviations are used: SNP, single-nucleotide polymorphism; STR, short tandem repeats.
a QSOX2 (MIM 612860), GPSM1 (MIM 609491).
b Nucleotides for SNHG7, a non-protein-coding gene, are numbered relative to the first base in the cDNA sequence of NR_024542.1.
c Previously unreported SNP.
d This previously unreported SNP found in SNHG7 does not cosegregate with deafness in family PKDF280. A meiotic break point in two affected subjects in this
family refined the proximal end of the DFNB79 linkage interval and excludes SNHG7 as a DFNB79 candidate gene.deletion (c.1244delC), an 11 bp duplication (c.44_54dup),
and an 11 bp deletion (c.42_52) cosegregating with deaf-
ness in families PKDF517, PKDF280, and PKDF1129,
respectively (Figure 1A). Each of the three mutations alters
the predicted open reading frame and introduces 66, 374,
and 149 missense amino acids followed by a stop codon,
respectively. The long missense open reading frames are
due to high GC content, because stop codons are AT-rich.
This phenomenon of long, open, altered reading frames
following a frameshift mutation in GC-rich exons has
been noted by others.22 The 11 bp duplication and 11 bp
deletion found in families PKDF280 and PKDF1129,
respectively, are overlapping. The 11 bp insertion produces
a nearly perfect tandem triplication of this sequence (Fig-
ure 1B). The 11 bp deletion removes one of two wild-
type tandem 11 bp duplications (Figures 1A and 1B) and
appears to be identical to a mutation of TPRN segregatingof bars. Note that in exon 1, a region of 878 bp that has 81%GC cont
array. We determined the sequence of this GC-rich region from PCR
fourDFNB79-linked pedigrees by using dideoxy-terminator chemistry
represent exons, introns, and the 30 UTR, respectively, of TPRN. See
The Ameriin an unrelated Moroccan family.23 All four mutations of
TPRN are located in exon 1 (Figure 3) and were not
observed in 488–500 control chromosomes from the Pakis-
tani population and 400 chromosomes from the Coriell
HD200CAU human variation panel (Table 3).
The DFNB79 linkage region on chromosome 9q34.3
shows conserved synteny with mouse chromosome 2qA3
(Figure 4A). ClustalW alignment of human and mouse
taperin (711 and 749 residues, respectively) shows that
there is 68% identity and 75% similarity (Figure 5 and Fig-
ure S1). On the basis of conserved synteny and sequence
similarity, mouse C430004E15Rik appears to be the ortho-
log of human TPRN. We designed primers for PCR ampliﬁ-
cation of cDNA of C430004E15Rik from two mouse
multiple-tissue cDNA panels (Clontech MTC panels I and
III) and from cochlear cDNA produced in our laboratory.
A single band corresponding to a transcript of 2.4 kb wasFigure 3. NimbleGen Probe Coverage
and Sequencing Coverage across TPRN,
GC Content and Locations of Four Patho-
genic Variants Found in DFNB79-Linked
Families
Approximately 10 kb spanning TPRN in
the 2.9 Mb DFNB79 interval is shown.
Vertical lines correspond to GC content
in a ﬁve-base window. The upper black
bars depict probe coverage (tiled regions)
of TPRN. Regions for which 454 sequence
was obtained are shown in the lower set
ent was not sequenced even though it was tiled on the NimbleGen
products ampliﬁed from genomic DNA of family members of the
. Grey-colored thick bars, lines joining them, and the thin gray bar
Table S3 as well.
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Figure 4. Conserved Synteny of a Part of
Human Chromosome 9q with Mouse
Chromosome 2 and Expression Profile of
TPRN in Several Tissues
(A) Part of human chromosome 9q, 17.71
Mb at the telomeric end, is syntenic to
14.62 Mb of mouse chromosome 2, which
also includes 2.9 Mb of the DFNB79
linkage interval. Vertical lines (not drawn
to scale) between the two chromosomal
segments show the syntenic region, with
ﬁve closely linked orthologous genes on
each side of theDFNB79 gene. On the basis
of conserved synteny and sequence com-
parison (see Figure 5), C430004E15Rik is
the mouse ortholog of human TPRN.
(B) Arrows indicate the position of the
forward and reverse primer used to amplify
the C430004E15Rik transcript frommouse
multiple-tissue cDNA libraries. Expected
cDNA and gDNA product sizes are 2.4 kb
and 6.9 kb, respectively. Amplimers were
sequence conﬁrmed.found in all cDNA samples tested (Figure 4B) and was
sequence veriﬁed. Although Tprn is expressed in many
organs and tissues, there were no other obvious clinical
ﬁndings besides the hearing loss in the individuals who
were homozygous for TPRN mutations.384 The American Journal of Human Genetics 86, 378–388, March 1Localization of Taperin in the Inner Ear
TPRN encodes an uncharacterized protein, which we
named taperin. The human RefSeq transcript (NM_
001128228.1) is predicted to encode 650 amino acids but
lacks a 50 UTR. In the Ensemble/Havana database of curatedFigure 5. ClustalW Alignment of Pre-
dicted Amino Acid Sequences Encoded
by Human TPRN and Its Mouse Ortholog
C430004E15Rik
Taperin (711 residues, Ensembl,
ENSP00000387100) has 68% identity and
75% similarity with the orthologous
mouse predicted protein of 749 amino
acids deduced from genomic DNA and
conﬁrmed by sequencing cDNA. Residues
located in the black-, gray-, and white-
colored blocks are identical, similar and
mismatched, respectively, and dots repre-
sent gaps. ‘‘M’’ on top of the black triangle
is the translation start site predicted for
human taperin (RefSeq, NP_001121700).
Note that the additional N-terminal 61
residues are highly conserved in themouse
ortholog. Red triangles point to the ﬁrst
affected amino acid due to the one
nonsense mutation and the three frame-
shift mutations segregating in the four
DFNB79-linked pedigrees. The rectangle
outlines the conservation of the human
protein residues that were used as an
immunogen for the commercially avail-
able antibody (Sigma-Aldrich) to taperin,
which we used to immunostain mouse
inner ear tissues. See also Figure S1 for
a ClustalW alignment of taperin with
multiple species.
2, 2010
Figure 6. Antibody Validation and Im-
munolocalization of Taperin in the Inner
Ear Sensory Epithelia
(A) COS7 cells transfected with an expres-
sion vector containing a cDNA construct
for full-length mouse taperin epitope
tagged with GFP.
(B and C) Staining of GFP-taperin-trans-
fected COS7 cells with taperin antibody.
The antibody immunoﬂuorescence signal
(red) colocalizes with GFP-taperin.
(D) COS7 cell transfected with full-length
GFP-phostensin (green) and stained with
taperin antibody (red). No colocalization
signal is observed, revealing no crossreac-
tivity of taperin antibody with phostensin.
(E–H) Rhodamine-phalloidin (red) in the
mouse organ of Corti and vestibular sen-
sory epithelium highlights ﬁlamentous
actin of stereocilia core, hair cell cuticular
plates, as well as cytoskeleton of nonsen-
sory cells. (E) An optical section of P7
mouse organ of Corti at the surface of the
reticular lamina. Taperin (green) is local-
ized at the base of each stereocilium of
outer hair cells (OHCs) and inner hair cells
(IHCs) at the top of the actin-rich cuticular
plate. Inset shows a higher-resolution
image of an OHC apical surface with
taperin (green) localized near the base of
each stereocilium from all three rows.
Taperin immunoreactivity is also present
in the supporting cells (SCs). The inner
sulcus cells (ISCs) and other cell types
outside of the sensory epithelium have weaker or no obvious taperin immunoreactivity. (F) Taperin (green) is present in the taper region
at the base of each stereocilium (arrow) of vestibular hair cells (VHCs) in the sensory epithelium of mouse saccule. (G and H) Higher-
resolution images of IHC stereocilia reveal distinct localization of taperin along the taper region near stereocilia bases at the apical surface
of P7 (G) and P45 (H) hair cells (arrows).
Scale bars in (C) and (D) represent 20 mm, and those in (E–H) represent 5 mm. See Figure S2 as well for a ClustalW alignment of human
taperin and human phostensin.genes, there are four isoforms of TPRN. The longest isoform
(ENST00000409012) extends the NM_001128228.1 RefSeq
annotation at the 50 end for an open reading frame encod-
ing a total of 711 residues. The additional 61 residues show
74% identity and 82% similarity to the N terminus of
mouse taperin (Figure 5). We consider the longer transcript
to be a more accurate representation of the human and
mouse ortholog on the basis of conservation of the open
reading frame at the 50 end.
Taperin appears to have no conserved domains or motifs
in the amino acid sequence predicted by SMART or BLAST
against the CDD database, although there are regions
of low complexity and intrinsic disorder, and there is a
low-probability predicted coiled-coil domain toward the
C terminus. A BLAST search of the nonredundant (NR)
protein database using the predicted 711-amino-acid-
long sequence identiﬁed a small region of low similarity
to only one other protein, phostensin (RefSeq NP_
597728). Phostensin was reported to be an actin ﬁlament
pointed-end-capping protein, which modulates actin
dynamics by targeting protein phosphatase 1 to the F-actin
cytoskeleton.24,25 A ClustalW alignment of taperin and
phostensin shows an overall 22% identity and 34% simi-The Amerilarity. In one region of 58 residues (543–600 of taperin,
ENSP00000387100), there is 56% identity and 76% simi-
larity between these two proteins (Figure S2).
A commercial antiserum from Sigma-Aldrich against
human C9orf75 (taperin) was raised against a fragment
70 amino acids in length (Figure 5). These 70 residues are
75% identical to the residues of the mouse ortholog and
have no obvious similarity to mouse phostensin. The anti-
serum to taperin was validated in heterologous cells, and
no crossreactivity with phostensin was observed (Figures
6A–6D). The immunolocalization of taperin was examined
in the mouse organ of Corti and vestibular sensory epithe-
lium (Figures 6E–6H). We observed taperin immunoreac-
tivity in the sensory epithelia of the organ of Corti and
vestibular end organs and, to a lesser extent, in Reisner’s
membrane and the spiral ligament. In the organ of Corti,
we found taperin within the supporting cells and in inner
ear hair cell stereocilia, in which immunoreactivity was
most prominent at the base of stereocilia where the diam-
eter of stereocilia gradually narrows (Figures 6G and 6H).
This region is referred to as the taper.26 Taperin was so
named because it highlights the taper region of each ster-
eocilium (Figures 6G and 6H).can Journal of Human Genetics 86, 378–388, March 12, 2010 385
Discussion
Targeted enrichment of a chromosomal interval in combi-
nation with next-generation sequencing has theoretically
simpliﬁed human disease-gene identiﬁcation, although
there are caveats. For example, CpG islands are associated
with the 50 ends of many genes in vertebrates and have
a high GC content.27 Highly GC-rich intervals covered
by probes are difﬁcult to capture and/or sequence. One
such unsequenced GC-rich region represented on theNim-
bleGen array is shown in Figure 3. Underrepresentation of
GC-rich regions from capture failure, sequencing dropout,
or both was previously noted.14 It is also worth noting that
twomutations of TPRN, c.42_52del and c.44_54dup, are in
a region represented on the custom NimbleGen DFNB79
capture array, but no DNA sequence from this part of
exon 1 was obtained (Figure 3). Thus, had we selected
an affected individual from either family PKDF1129 or
PKDF280 for NimbleGen capture and 454 sequencing, we
probably would not have discovered aDFNB79 pathogenic
mutation by using this particular disease-gene-discovery
strategy. Therefore, to increase the probability of a success-
ful disease-gene identiﬁcation by using this technology, we
suggest using genomic DNA from affected members of
different families expected to have different allelic muta-
tions. It will be of interest to determine which of the
various alternative targeted capture and next-generation
sequencing technologies work best for regions of high
GC content.
There were 303 putative previously unreported variants
found in theDFNB79 target region.We independently eval-
uated 17 of these variants by Sanger sequencing and found
that only eight were true positives. Each of the eight
authentic variants shared the characteristic of being sup-
ported by at least 85% of the 454 reads. We retrospectively
applied this additional criterion to the original data set.
The new criterion requires that variants be supported by
at least 85% of the reads in a given contig, in addition to
the original criterion that a contig comprise at least three
nonduplicate forward and reverse 454 reads, or at least
ﬁve unidirectional reads, with quality scores > 20 (or > 30
if the difference involves a homopolymer of ﬁve or more
nucleotides or larger). Thesenewcriteria reduce thenumber
of putative variants in theDFNB79 target region from303 to
159 (values in bold in Figure 2). It is clear that it is helpful to
have reference DNA sequences from ethnically matched
individuals in order to distinguish polymorphisms from
pathogenic mutations. Also, the likelihood of 159 novel
variants in less than 2.9Mb of genomic DNA of one subject
highlights the importanceof combiningdata frommultiple
families at a genetically well-deﬁned locus. It also suggests
that ﬁnding a causative mutation by whole-genome
sequencing of a singleton is going to be problematic.
TPRN encodes taperin, which is concentrated at the
taper region of stereocilia (Figure 6). Within the taper,
the peripheral ﬁlaments of the actin core have pointed
ends terminating at different levels, whereas actin ﬁla-386 The American Journal of Human Genetics 86, 378–388, March 1ments in the center of stereocilia core continue uninter-
rupted through the taper region.26 The most prominent
immunolocalization signal for taperin was present at the
taper of inner hair cells, but immunoreactivity was also de-
tected in the less obvious taper regions of outer hair cell
and vestibular hair cell stereocilia (Figures 6E and 6F).
The speciﬁc concentration of taperin in the stereocilia
taper region and the signiﬁcant but limited sequence simi-
larity to phostensin prompts speculation that taperin may
also modulate actin dynamics through direct or indirect
interaction with pointed ends of actin ﬁlaments speciﬁ-
cally within the hair cell stereocilia. Also, we cannot
exclude the possible involvement of taperin in the forma-
tion or maintenance of ankle links of stereocilia or interac-
tions with proteins found near the base of stereocilia, such
as PTPRQ,28,29 VLGR1,30 whirlin,31–33 usherin,34 and veza-
tin.33,35 Ankle links, ﬁlamentous connections between
stereocilia, are transient structures that disappear after
postnatal day 12 in mice.36 In contrast, taperin is present
at the taper region in adult mouse stereocilia (Figure 6H),
suggesting some other function in addition to, or unre-
lated to, ankle links.
We conclude that mutations of TPRN are the cause
of hearing loss, because (1) a nonsense mutation
c.1056G>A found in TPRN is the only potentially patho-
genic variant identiﬁed by capture and sequencing of
nearly the entire DFNB79 interval in one affected indi-
vidual from family PKDF741, and (2) a total of four trun-
cating mutations cosegregate with the deafness phenotype
in four DFNB79-linked families and are not found in
normal controls. Furthermore, despite a ubiquitous expres-
sion pattern, taperin appears to have only a crucial func-
tion in the inner ear. The distinct pattern of taperin expres-
sion in sensory hair cells and nonsensory cells of the organ
of Corti suggests multiple possible pathogenic mecha-
nisms causing DFNB79 deafness. Understanding the
precise cause of deafness due to mutations of TPRN will
require an appropriate mouse model and more detailed
analyses of the expression pattern in different inner ear
cell types, as well as a biochemical characterization of
taperin function.Supplemental Data
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